Alignment Healthcare, Inc. Common Stock
ALHC
$13.96
+3.71%
Alignment Healthcare, Inc. is a next-generation, consumer-centric healthcare platform that provides Medicare Advantage plans to seniors, leveraging a proprietary technology platform and clinical model to improve health outcomes. The company operates in the highly competitive Medicare Advantage sector, differentiating itself through a direct-to-consumer sales approach and a focus on value-based care. Currently, the stock is under significant pressure following a sharp decline in late July 2026, likely driven by concerns over rising medical costs or competitive dynamics, despite recent positive catalysts such as inclusion in the S&P SmallCap 600 and favorable CMS Medicare payment increases. Investor attention is focused on the company's ability to sustain its high revenue growth while achieving profitability, as it transitions from a high-growth, loss-making phase to a more mature, profitable trajectory.…
ALHC
Alignment Healthcare, Inc. Common Stock
$13.96
Related headlines
Investment Opinion: Should I buy ALHC Today?
Based on the strong revenue growth, improving profitability, and bullish analyst consensus, I rate ALHC a Buy. The average analyst target of $24.08 implies 76% upside, and the stock is trading at a significant discount to its historical PS ratio of 1.48x-13.38x. The company's revenue growth of 44.4% YoY and positive free cash flow of $123.7M support the thesis that it is on a path to profitability.
Sign up to view all
ALHC 12-Month Price Forecast
The AI assessment is bullish, driven by the company's strong growth, improving profitability, and attractive valuation. The recent sell-off appears overdone, and the analyst targets suggest significant upside. However, the high volatility and thin margins warrant caution. The stance would be upgraded to high confidence if the company reports another quarter of positive EPS and maintains revenue growth above 40%. It would be downgraded to neutral if margins deteriorate or growth slows below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $24.08 and implied upside of +72.5% versus the current price.
Average Target
$24.08
0 analysts
Implied Upside
+72.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$16 - $30
Analyst target range
Analyst coverage is robust with 13 analysts, and the consensus recommendation is 'Strong Buy' with a mean rating of 1.5 (where 1 is Strong Buy and 5 is Sell). The average target price is $24.08, implying a substantial 76.0% upside from the current price of $13.68, and the distribution shows 0 sells, 1 hold, and 12 buys, indicating a highly bullish sentiment. The target price range spans from $16.00 (low) to $30.00 (high), with the high target suggesting that analysts see potential for the stock to more than double, likely driven by expectations of continued revenue growth and margin expansion, while the low target still represents a 17% upside, reflecting confidence in the company's fundamentals. Recent institutional ratings show a mix of Overweight and Neutral actions, with JP Morgan upgrading from Neutral to Overweight in November 2025, and the wide spread between low and high targets indicates high uncertainty, but the overall bullish consensus suggests that the recent sell-off may be overdone.
Bulls vs Bears: ALHC Investment Factors
Alignment Healthcare presents a classic high-growth, high-risk investment case. On the bull side, revenue growth is exceptional at 44.4% YoY, profitability is improving, and analyst sentiment is overwhelmingly positive with a 76% upside to the average target. On the bear side, the stock has collapsed 44% in a month, margins are razor-thin, and the forward PE of 18x leaves little room for error. The most important tension is whether the company can sustain its growth while achieving profitability—if it does, the stock is deeply undervalued; if not, the current price may still be too high. Currently, the evidence slightly favors the bull case given the strong growth and analyst consensus, but the recent sell-off highlights significant near-term risks.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 44.4% YoY to $1.013B, with consistent growth from $628.6M in Q1 2024 to over $1B in Q2 and Q4 2025. This demonstrates robust demand for Medicare Advantage plans and successful market expansion.
- Improving Profitability: Net loss narrowed from $31.1M in Q4 2024 to $11.0M in Q4 2025, a 65% improvement. The company also achieved positive net income in Q2 and Q3 2025, signaling a clear path to sustained profitability.
- Positive Free Cash Flow: Trailing twelve-month free cash flow is $123.7M, indicating improving cash generation and financial flexibility. This is a key milestone for a growth company transitioning to maturity.
- Bullish Analyst Sentiment: Consensus rating is Strong Buy with a mean rating of 1.5 (1=Strong Buy, 5=Sell). Average target price of $24.08 implies 76% upside from the current price of $13.68, with 12 buys and only 1 hold.
Bearish
- Severe Stock Decline: The stock has fallen 44.3% in the past month and is trading near its 52-week low of $13.05, just 5% above it. This sharp sell-off reflects significant investor concerns about medical costs and competitive pressures.
- Thin Gross Margins: Gross margin was only 10.5% in Q4 2025, down from 12.3% in Q4 2024. This leaves little room for error and makes the company vulnerable to cost inflation or pricing pressure.
- High Valuation on Forward Earnings: Forward PE of 18.18x assumes a rapid earnings turnaround, but trailing earnings are negative. If profitability disappoints, the stock could face significant de-rating.
- Insider Selling: The vice chairman sold 25,000 shares in June 2026, part of a pattern of insider selling. While planned, it can signal a lack of confidence in the stock's near-term prospects.
ALHC Technical Analysis
Alignment Healthcare's stock has experienced a volatile and predominantly downward trend over the past year, with the current price of $13.68 representing a 2.0% gain over the 12-month period but a significant 44.3% decline over the past month. The stock is trading near the bottom of its 52-week range, at approximately 5% above the low of $13.05 and 45.6% below the high of $25.12, indicating that the stock is in a severe downtrend and near its lowest levels, which could signal either a value opportunity or a falling knife. The 1-year price change of +2.0% masks the extreme volatility, as the stock has swung from highs above $24 in June 2026 to current lows, reflecting a sharp reversal in investor sentiment.
Beta
1.13
1.13x market volatility
Max Drawdown
-46.3%
Largest decline past year
52-Week Range
$13-$25
Price range past year
Annual Return
-5.8%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | -33.3% | +4.5% |
| 3m | -11.3% | +5.1% |
| 6m | -30.9% | +13.7% |
| 1y | -5.8% | +20.6% |
| ytd | -31.0% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Alignment Healthcare has demonstrated robust revenue growth, with the most recent quarter (Q4 2025) reporting revenue of $1.013 billion, a 44.4% year-over-year increase, and the company has consistently grown revenue from $628.6 million in Q1 2024 to over $1 billion in Q2 and Q4 2025. However, profitability remains elusive, as the company reported a net loss of $11.0 million in Q4 2025, although this is a significant improvement from the $31.1 million loss in Q4 2024, and the gross margin has been relatively stable around 10-13%, with Q4 2025 gross margin at 10.5%. The company's balance sheet shows a debt-to-equity ratio of 1.84, indicating moderate leverage, but it generated positive free cash flow of $123.7 million on a trailing twelve-month basis, suggesting improving cash generation, though the current ratio of 1.71 indicates adequate liquidity.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+44.4%
YoY Comparison
Gross Margin
10.5%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Given that Alignment Healthcare has negative trailing earnings (net income of -$11.0 million in Q4 2025), the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 0.99x, it is relatively low for a high-growth healthcare company, suggesting the market is pricing in significant growth expectations. The forward PE ratio of 18.18x indicates that analysts expect the company to become profitable in the next year, and the gap between the negative trailing PE and positive forward PE implies a rapid earnings turnaround is anticipated. Compared to the industry average PS ratio of approximately 1.5x (based on typical managed care companies), ALHC trades at a 34% discount, which may be justified by its lower margins and higher risk profile, but also presents potential upside if the company can execute on its growth plans. Historically, ALHC's PS ratio has ranged from 1.48x to 13.38x over the past five years, and the current 0.99x is near the historical low, indicating that the stock is trading at a significant discount to its own valuation history, which could reflect either a value opportunity or deteriorating fundamentals.
PE
-5337.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
80.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company's net loss of $11.0M in Q4 2025, though improved, shows that profitability is not yet consistent. Gross margins of 10.5% are thin, leaving little buffer against cost overruns or pricing pressure. The debt-to-equity ratio of 1.84 indicates moderate leverage, and while free cash flow is positive at $123.7M TTM, the company's reliance on continued growth to justify its valuation is a key risk. If revenue growth decelerates or margins compress further, the stock could face severe downside.